Literature DB >> 2859158

The pharmacokinetics of cyclosporine. II. Blood plasma distribution and binding studies.

W M Awni, R J Sawchuk.   

Abstract

The pharmacokinetic consequences of alterations in the blood plasma distribution of cyclosporine are examined in this study. A series of solutions of cyclosporine of known concentration were prepared in rabbit blood. The plasma, separated at 37 degrees C, was then assayed for cyclosporine using an HPLC method. A mathematical model relating the blood and plasma concentrations of cyclosporine at equilibrium was derived and used to fit the data. The model assumes that the free fraction of the drug in plasma (fp) is constant but that the free fraction in blood is not. In the rabbit, fp was estimated to equal 0.405. This may be attributed to cyclosporine binding to lipoproteins, and to the lower concentrations of lipoproteins in rabbit serum compared to that in human serum. The capacity factor and the binding affinity constant of the drug for blood cells were estimated to equal 3590 micrograms/liter and 0.00682 liter/microgram in the rabbit. These results and the findings of a previous study suggest that the free fraction of the drug in blood increased, while the free intrinsic clearance did not change, with increases in the steady state blood concentration of the drug. It was concluded that the changes in binding characteristics of cyclosporine in blood at higher concentration and not the changes in the metabolic activity of the liver, as measured by intrinsic clearance, are responsible for the nonlinear pharmacokinetic behavior exhibited by cyclosporine in the rabbit.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2859158

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  7 in total

Review 1.  Role of plasma lipoproteins in modifying the toxic effects of water-insoluble drugs: studies with cyclosporine A.

Authors:  Kishor M Wasan; Manisha Ramaswamy; Mona Kwong; Kathy D Boulanger
Journal:  AAPS PharmSci       Date:  2002

2.  The binding of cyclosporin A to human plasma: an in vitro microdialysis study.

Authors:  H Yang; W F Elmquist
Journal:  Pharm Res       Date:  1996-04       Impact factor: 4.200

3.  Saturable binding of cyclosporin A to erythrocytes: estimation of binding parameters in renal transplant patients and implications for bioavailability assessment.

Authors:  B Legg; M Rowland
Journal:  Pharm Res       Date:  1988-02       Impact factor: 4.200

Review 4.  Cyclosporin pharmacokinetics in paediatric transplant recipients.

Authors:  G F Cooney; K Habucky; K Hoppu
Journal:  Clin Pharmacokinet       Date:  1997-06       Impact factor: 6.447

5.  On the dose dependency of cyclosporin A absorption and disposition in healthy volunteers.

Authors:  J P Reymond; J L Steimer; W Niederberger
Journal:  J Pharmacokinet Biopharm       Date:  1988-08

6.  Differences in lipoprotein lipid concentration and composition modify the plasma distribution of cyclosporine.

Authors:  K M Wasan; P H Pritchard; M Ramaswamy; W Wong; E M Donnachie; L J Brunner
Journal:  Pharm Res       Date:  1997-11       Impact factor: 4.200

7.  Modifications in lipoprotein surface charge alter cyclosporine A association with low-density lipoproteins.

Authors:  Kishor M Wasan; Olena Sivak
Journal:  Pharm Res       Date:  2003-01       Impact factor: 4.200

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.